Fulton Bank N.A. cut its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 52.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,295 shares of the company’s stock after selling 8,127 shares during the period. Fulton Bank N.A.’s holdings in Astrazeneca were worth $1,439,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Astrazeneca by 552.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after acquiring an additional 4,697,895 shares during the last quarter. Pictet Asset Management Holding SA acquired a new stake in Astrazeneca in the 1st quarter valued at approximately $675,263,000. Bank of Montreal Can raised its position in Astrazeneca by 344.6% in the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after purchasing an additional 2,695,793 shares during the period. Lansforsakringar Fondforvaltning AB publ purchased a new stake in Astrazeneca in the first quarter valued at approximately $473,782,000. Finally, ABN AMRO Bank N.V. lifted its stake in Astrazeneca by 32,441.5% during the first quarter. ABN AMRO Bank N.V. now owns 2,445,171 shares of the company’s stock worth $482,158,000 after purchasing an additional 2,437,657 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca News Roundup
Here are the key news stories impacting Astrazeneca this week:
- Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
- Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
- Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
- Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
- Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.
Astrazeneca Stock Performance
Astrazeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, research analysts predict that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
AZN has been the subject of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.
Check Out Our Latest Research Report on Astrazeneca
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
